We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
PureTech Health PLC | NASDAQ:PRTC | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 29.80 | 11.43 | 45.71 | 28.74 | 28.40 | 28.74 | 129 | 22:00:00 |
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Tuesday, June 13, 2023.
All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below. All resolutions were passed by greater than 93% of the shares voted at the meeting.
Resolutions
For
%
Against
%
Withheld
Total votes cast
001. To approve the Company’s Annual Report and Accounts for year ended 31 December 2022
218,239,144
100.00%
0
0.00%
1,856
218,239,144
002. To approve the Directors’ Remuneration Report
208,436,087
95.51%
9,804,137
4.49%
776
218,240,224
003. To elect Ms. Sharon Barber-Lui as a director
217,708,896
99.76%
530,758
0.24%
1,346
218,239,654
004. To elect Dr. Raju Kucherlapati as a director
217,673,486
99.74%
564,168
0.26%
3,346
218,237,654
005. To elect Dr. John LaMattina as a director
208,905,865
95.72%
9,331,788
4.28%
3,347
218,237,653
006. To elect Ms. Kiran Mazumdar-Shaw as a director
204,963,784
93.92%
13,275,369
6.08%
1,847
218,239,153
007. To elect Dr. Robert Langer as a director
213,495,366
97.83%
4,743,812
2.17%
1,822
218,239,178
008. To elect Ms. Daphne Zohar as a director
218,236,986
100.00%
2,693
0.00%
1,321
218,239,679
009. To elect Dr. Bharatt Chowrira as a director
217,679,376
99.99%
30,161
0.01%
531,463
217,709,537
010. To appoint PricewaterhouseCoopers LLP as the auditors of the Company
217,704,419
99.75%
535,776
0.25%
805
218,240,195
011. To authorize the Audit Committee to determine the Auditors' remuneration
218,232,344
100.00%
6,151
0.00%
2,505
218,238,495
012. To authorize the allotment of shares
218,208,524
99.99%
31,471
0.01%
1,005
218,239,995
013. To approve the Company’s new Performance Share Plan
211,285,130
96.81%
6,952,233
3.19%
3,637
218,237,363
014. To disapply pre-emption rights
217,137,254
99.50%
1,101,010
0.50%
2,736
218,238,264
015. To further disapply pre-emption rights as if section 561 of the Companies Act 2006 did not apply to any allotment of equity securities for cash or sale of treasury shares for cash
214,933,920
98.49%
3,304,344
1.51%
2,736
218,238,264
016. To authorize market purchase of own shares
217,711,818
99.76%
528,167
0.24%
1,015
218,239,985
017. To authorize general meetings to be called on not less than 14 clear days’ notice
217,917,408
99.85%
322,238
0.15%
1,354
218,239,646
Notes:
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that is expected to be filed soon for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230613241795/en/
PureTech Investor Relations IR@puretechhealth.com
1 Year PureTech Health Chart |
1 Month PureTech Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions